Alloimmunity to RhD in humans

Stanislaw Urbaniak

    Research output: Contribution to journalArticle

    13 Citations (Scopus)

    Abstract

    The RhD protein is expressed only on human red blood cells (RBC), and is one of the most immunogenic of the blood groups. It is of clinical importance since the alloantibody (anti-D) can hemolyse D positive RBC after blood transfusion, or cause hemolytic disease of the newborn. The immunogenicity of D is better understood with the knowledge of the genetic basis of the protein(s) involved, the molecular orientation in the RBC membrane, and the nature of the cellular immune response to proteins. The adaptive humoral response consists of antigen presenting cells, T-cells and B-cells, which interact cooperatively to result in antibody against the antigen in question. The anti-D that B-cells produce is targeted against Surface membrane determinants (B-cell epitopes) and are conformational i.e. non-contiguous amino acids. The antigen specific T-cells recognize short linear peptides in the context of MHC class 11, and these T-cell epitopes can reside anywhere in the protein. Since the RhD protein in D-positive individuals differs by some 35 amino acids from the RhCcEe protein in D-negative individuals, the Opportunity for generating immunogenic T-cell epitopes is much greater than that for alleles characterized by a single amino acid difference e.g. E and e. Multiple conformational B-cell epitopes are also created by the presence of several D-specific amino acids in extracellular loops on the red cells surface, which may stimulate several B-cell clones and develop a strong polyclonal antibody response. With greater understanding comes the possibility of manipulating the immune response to D in clinical situations. (c) 2006 Elsevier SAS. All rights reserved.

    Original languageEnglish
    Pages (from-to)19-22
    Number of pages3
    JournalTransfusion clinique et biologique
    Volume13
    DOIs
    Publication statusPublished - 2006

    Keywords

    • RhD
    • anti-D
    • immune response
    • B-cell epitopes
    • T-cell epitopes
    • TRANSFUSION
    • EPITOPES
    • PROTEIN
    • CELLS

    Cite this

    Alloimmunity to RhD in humans. / Urbaniak, Stanislaw.

    In: Transfusion clinique et biologique, Vol. 13, 2006, p. 19-22.

    Research output: Contribution to journalArticle

    Urbaniak, Stanislaw. / Alloimmunity to RhD in humans. In: Transfusion clinique et biologique. 2006 ; Vol. 13. pp. 19-22.
    @article{c94241b4477d4928abb43de321742ccc,
    title = "Alloimmunity to RhD in humans",
    abstract = "The RhD protein is expressed only on human red blood cells (RBC), and is one of the most immunogenic of the blood groups. It is of clinical importance since the alloantibody (anti-D) can hemolyse D positive RBC after blood transfusion, or cause hemolytic disease of the newborn. The immunogenicity of D is better understood with the knowledge of the genetic basis of the protein(s) involved, the molecular orientation in the RBC membrane, and the nature of the cellular immune response to proteins. The adaptive humoral response consists of antigen presenting cells, T-cells and B-cells, which interact cooperatively to result in antibody against the antigen in question. The anti-D that B-cells produce is targeted against Surface membrane determinants (B-cell epitopes) and are conformational i.e. non-contiguous amino acids. The antigen specific T-cells recognize short linear peptides in the context of MHC class 11, and these T-cell epitopes can reside anywhere in the protein. Since the RhD protein in D-positive individuals differs by some 35 amino acids from the RhCcEe protein in D-negative individuals, the Opportunity for generating immunogenic T-cell epitopes is much greater than that for alleles characterized by a single amino acid difference e.g. E and e. Multiple conformational B-cell epitopes are also created by the presence of several D-specific amino acids in extracellular loops on the red cells surface, which may stimulate several B-cell clones and develop a strong polyclonal antibody response. With greater understanding comes the possibility of manipulating the immune response to D in clinical situations. (c) 2006 Elsevier SAS. All rights reserved.",
    keywords = "RhD, anti-D, immune response, B-cell epitopes, T-cell epitopes, TRANSFUSION, EPITOPES, PROTEIN, CELLS",
    author = "Stanislaw Urbaniak",
    year = "2006",
    doi = "10.1016/j.tracli.2006.02.020",
    language = "English",
    volume = "13",
    pages = "19--22",
    journal = "Transfusion clinique et biologique",
    issn = "1246-7820",
    publisher = "Elsevier Masson",

    }

    TY - JOUR

    T1 - Alloimmunity to RhD in humans

    AU - Urbaniak, Stanislaw

    PY - 2006

    Y1 - 2006

    N2 - The RhD protein is expressed only on human red blood cells (RBC), and is one of the most immunogenic of the blood groups. It is of clinical importance since the alloantibody (anti-D) can hemolyse D positive RBC after blood transfusion, or cause hemolytic disease of the newborn. The immunogenicity of D is better understood with the knowledge of the genetic basis of the protein(s) involved, the molecular orientation in the RBC membrane, and the nature of the cellular immune response to proteins. The adaptive humoral response consists of antigen presenting cells, T-cells and B-cells, which interact cooperatively to result in antibody against the antigen in question. The anti-D that B-cells produce is targeted against Surface membrane determinants (B-cell epitopes) and are conformational i.e. non-contiguous amino acids. The antigen specific T-cells recognize short linear peptides in the context of MHC class 11, and these T-cell epitopes can reside anywhere in the protein. Since the RhD protein in D-positive individuals differs by some 35 amino acids from the RhCcEe protein in D-negative individuals, the Opportunity for generating immunogenic T-cell epitopes is much greater than that for alleles characterized by a single amino acid difference e.g. E and e. Multiple conformational B-cell epitopes are also created by the presence of several D-specific amino acids in extracellular loops on the red cells surface, which may stimulate several B-cell clones and develop a strong polyclonal antibody response. With greater understanding comes the possibility of manipulating the immune response to D in clinical situations. (c) 2006 Elsevier SAS. All rights reserved.

    AB - The RhD protein is expressed only on human red blood cells (RBC), and is one of the most immunogenic of the blood groups. It is of clinical importance since the alloantibody (anti-D) can hemolyse D positive RBC after blood transfusion, or cause hemolytic disease of the newborn. The immunogenicity of D is better understood with the knowledge of the genetic basis of the protein(s) involved, the molecular orientation in the RBC membrane, and the nature of the cellular immune response to proteins. The adaptive humoral response consists of antigen presenting cells, T-cells and B-cells, which interact cooperatively to result in antibody against the antigen in question. The anti-D that B-cells produce is targeted against Surface membrane determinants (B-cell epitopes) and are conformational i.e. non-contiguous amino acids. The antigen specific T-cells recognize short linear peptides in the context of MHC class 11, and these T-cell epitopes can reside anywhere in the protein. Since the RhD protein in D-positive individuals differs by some 35 amino acids from the RhCcEe protein in D-negative individuals, the Opportunity for generating immunogenic T-cell epitopes is much greater than that for alleles characterized by a single amino acid difference e.g. E and e. Multiple conformational B-cell epitopes are also created by the presence of several D-specific amino acids in extracellular loops on the red cells surface, which may stimulate several B-cell clones and develop a strong polyclonal antibody response. With greater understanding comes the possibility of manipulating the immune response to D in clinical situations. (c) 2006 Elsevier SAS. All rights reserved.

    KW - RhD

    KW - anti-D

    KW - immune response

    KW - B-cell epitopes

    KW - T-cell epitopes

    KW - TRANSFUSION

    KW - EPITOPES

    KW - PROTEIN

    KW - CELLS

    U2 - 10.1016/j.tracli.2006.02.020

    DO - 10.1016/j.tracli.2006.02.020

    M3 - Article

    VL - 13

    SP - 19

    EP - 22

    JO - Transfusion clinique et biologique

    JF - Transfusion clinique et biologique

    SN - 1246-7820

    ER -